Citation Impact
Citing Papers
rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data
2014 Standout
Induction of human neuronal cells by defined transcription factors
2011 StandoutNatureNobel
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
2013 Standout
Identification of genes in toxicity pathways of trinucleotide-repeat RNA in C. elegans
2014 StandoutNobel
Introducing sense into nonsense in treatments of human genetic diseases
2008
Molecular mechanisms of antibiotic resistance
2014 Standout
A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells
2010
Clarifying lysosomal storage diseases
2011
Cystic fibrosis
2016 Standout
Rise and dissemination of aminoglycoside resistance: the aac(6′)-Ib paradigm
2013
The role of autophagy in neurodegenerative disease
2013 Standout
Modeling familial Alzheimer's disease with induced pluripotent stem cells
2011 StandoutNobel
Systemic aminoglycoside treatment in rodent models of retinitis pigmentosa
2008
Drug Studies on Rett Syndrome: From Bench to Bedside
2020
The Use of Induced Pluripotent Stem Cells in Drug Development
2011 StandoutNobel
COVID-19: A promising cure for the global panic
2020 Standout
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
2017 StandoutNobel
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
2018
RNA and Disease
2009
DNA Methylation and Its Basic Function
2012 Standout
Cystic fibrosis genetics: from molecular understanding to clinical application
2014 Standout
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
Insights into RNA Biology from an Atlas of Mammalian mRNA-Binding Proteins
2012 Standout
Complexities of Rett Syndrome and MeCP2: Figure 1.
2011
Update on Key Emerging Challenges in Cystic Fibrosis
2014 Standout
Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases
2010
Induced Neuronal Cells: How to Make and Define a Neuron
2011 StandoutNobel
Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis
2010
Comparing aminoglycoside binding sites in bacterial ribosomal RNA and aminoglycoside modifying enzymes
2012
Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor
2013
Cigarette Smoke Induces Systemic Defects in Cystic Fibrosis Transmembrane Conductance Regulator Function
2013
The unfolded protein response affects readthrough of premature termination codons
2014
Derivation Conditions Impact X-Inactivation Status in Female Human Induced Pluripotent Stem Cells
2012 StandoutNobel
Aminoglycoside Antibiotics in the 21st Century
2012
Bacterial Antibiotic Resistance: The Most Critical Pathogens
2021 Standout
Toxicity Modulation, Resistance Enzyme Evasion, and A-Site X-ray Structure of Broad-Spectrum Antibacterial Neomycin Analogs
2014
Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy
2014 StandoutNobel
Ataluren as an Agent for Therapeutic Nonsense Suppression
2012
Neurons generated by direct conversion of fibroblasts reproduce synaptic phenotype caused by autism-associated neuroligin-3 mutation
2013 StandoutNobel
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Severe Retinal Degeneration Caused by a Novel Rhodopsin Mutation
2010 StandoutNobel
Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124)
2010
Works of Igor Nudelman being referenced
Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
2010
Differential Selectivity of Natural and Synthetic Aminoglycosides towards the Eukaryotic and Prokaryotic Decoding A Sites
2007
Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
2011
Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations
2011
In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome
2007
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations
2006
Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations
2010
Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases
2007
Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations
2009
Overexpression and Initial Characterization of the Chromosomal Aminoglycoside 3′- O -Phosphotransferase APH(3′)-IIb from Pseudomonas aeruginosa
2007